Integer (NYSE:ITGR) Releases Earnings Results

Integer (NYSE:ITGR) released its quarterly earnings data on Thursday. The medical equipment provider reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.02, Briefing.com reports. The business had revenue of $414.80 million during the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $0.87 EPS. Integer updated its FY24 guidance to $5.01-5.43 EPS and its FY 2024 guidance to 5.010-5.430 EPS.

Integer Price Performance

NYSE:ITGR opened at $109.59 on Friday. Integer has a 12 month low of $69.40 and a 12 month high of $123.99. The stock has a 50 day moving average of $113.11 and a two-hundred day moving average of $99.78. The company has a current ratio of 3.32, a quick ratio of 1.71 and a debt-to-equity ratio of 0.76. The firm has a market cap of $3.67 billion, a P/E ratio of 37.92, a price-to-earnings-growth ratio of 1.54 and a beta of 1.10.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. CL King assumed coverage on Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 price objective for the company. KeyCorp lifted their price target on Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. Bank of America upgraded Integer from a “neutral” rating to a “buy” rating and lifted their price target for the company from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, Benchmark restated a “buy” rating and issued a $130.00 price target on shares of Integer in a research note on Friday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Integer has a consensus rating of “Moderate Buy” and a consensus price target of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.